DE60022227D1 - 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung - Google Patents

2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung

Info

Publication number
DE60022227D1
DE60022227D1 DE60022227T DE60022227T DE60022227D1 DE 60022227 D1 DE60022227 D1 DE 60022227D1 DE 60022227 T DE60022227 T DE 60022227T DE 60022227 T DE60022227 T DE 60022227T DE 60022227 D1 DE60022227 D1 DE 60022227D1
Authority
DE
Germany
Prior art keywords
indol
oxo
acetamide
antitumoral effect
antitumoral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60022227T
Other languages
English (en)
Other versions
DE60022227T2 (de
Inventor
Ernesto Menta
Nicoletta Pescalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapeutics Europe SRL
Original Assignee
Cell Therapeutics Europe SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Europe SRL filed Critical Cell Therapeutics Europe SRL
Application granted granted Critical
Publication of DE60022227D1 publication Critical patent/DE60022227D1/de
Publication of DE60022227T2 publication Critical patent/DE60022227T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60022227T 1999-12-23 2000-12-21 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung Expired - Fee Related DE60022227T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI992693 1999-12-23
IT1999MI002693A IT1315267B1 (it) 1999-12-23 1999-12-23 Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
PCT/EP2000/013068 WO2001047916A1 (en) 1999-12-23 2000-12-21 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity

Publications (2)

Publication Number Publication Date
DE60022227D1 true DE60022227D1 (de) 2005-09-29
DE60022227T2 DE60022227T2 (de) 2006-06-22

Family

ID=11384182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022227T Expired - Fee Related DE60022227T2 (de) 1999-12-23 2000-12-21 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung

Country Status (24)

Country Link
US (1) US6753342B2 (de)
EP (1) EP1244652B1 (de)
JP (1) JP2003519140A (de)
KR (1) KR100795533B1 (de)
CN (1) CN1250542C (de)
AT (1) ATE302772T1 (de)
AU (1) AU776332B2 (de)
BR (1) BR0016553A (de)
CA (1) CA2395205A1 (de)
CZ (1) CZ20022170A3 (de)
DE (1) DE60022227T2 (de)
EA (1) EA004925B1 (de)
ES (1) ES2246918T3 (de)
HU (1) HUP0203524A3 (de)
IL (2) IL150329A0 (de)
IT (1) IT1315267B1 (de)
MX (1) MXPA02006217A (de)
NO (1) NO323312B1 (de)
NZ (1) NZ519689A (de)
PL (1) PL356541A1 (de)
SK (1) SK285682B6 (de)
TR (1) TR200201613T2 (de)
WO (1) WO2001047916A1 (de)
ZA (1) ZA200204964B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3842043B2 (ja) 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
CA2767092C (en) * 2002-07-09 2013-10-15 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same and methods of use for same
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
ES2345662T3 (es) * 2004-03-11 2010-09-29 Actelion Pharmaceuticals Ltd. Derivados de acido indol-1-il-acetico.
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RU2451018C2 (ru) 2006-04-07 2012-05-20 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы атф-связывающих кассетных транспортеров
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
JP5406716B2 (ja) * 2006-08-07 2014-02-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド インドール化合物
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012012204A (es) 2010-04-22 2012-12-05 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
CN115785079B (zh) * 2022-11-28 2024-02-13 沈阳药科大学 4-(1h-吲哚-5-基)氨基呋喃-2(5h)-酮类化合物及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0841924T3 (da) * 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
CO4970714A1 (es) 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
JP3842043B2 (ja) * 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法

Also Published As

Publication number Publication date
HUP0203524A2 (hu) 2003-03-28
ZA200204964B (en) 2004-01-29
ES2246918T3 (es) 2006-03-01
KR20020063247A (ko) 2002-08-01
NO323312B1 (no) 2007-03-12
IT1315267B1 (it) 2003-02-03
HUP0203524A3 (en) 2008-01-28
IL150329A0 (en) 2002-12-01
NO20022976L (no) 2002-06-20
BR0016553A (pt) 2002-09-17
EA200200558A1 (ru) 2002-12-26
SK8962002A3 (en) 2002-11-06
ATE302772T1 (de) 2005-09-15
SK285682B6 (sk) 2007-06-07
NZ519689A (en) 2004-02-27
MXPA02006217A (es) 2004-02-26
ITMI992693A1 (it) 2001-06-23
JP2003519140A (ja) 2003-06-17
US20030158153A1 (en) 2003-08-21
DE60022227T2 (de) 2006-06-22
CN1413205A (zh) 2003-04-23
EP1244652B1 (de) 2005-08-24
KR100795533B1 (ko) 2008-01-16
EP1244652A1 (de) 2002-10-02
ITMI992693A0 (it) 1999-12-23
NO20022976D0 (no) 2002-06-20
IL150329A (en) 2006-07-05
US6753342B2 (en) 2004-06-22
CA2395205A1 (en) 2001-07-05
CZ20022170A3 (cs) 2002-09-11
EA004925B1 (ru) 2004-10-28
PL356541A1 (en) 2004-06-28
WO2001047916A1 (en) 2001-07-05
CN1250542C (zh) 2006-04-12
AU776332B2 (en) 2004-09-02
TR200201613T2 (tr) 2002-10-21
AU2170401A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
DE60022227D1 (de) 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung
DE69918422D1 (de) Phthalazinone pde iii/iv hemmer
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
TR199901653T2 (xx) Fitalazinonlar.
DK1042319T3 (da) Dihydrobenzofuraner
MY128709A (en) Phosphonites
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
DE60005689D1 (de) Neue aminobenzophenone
SE9903290D0 (sv) Novel compounds
ATE287403T1 (de) 6-phenylbenzonaphthyidine
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
MA24197A1 (fr) Nouvelles fungarrestines
ES2159489A1 (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
ATE243698T1 (de) 1,2-dihydro-1-oxo-pyrazino(1,2-)indolederivate
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ES2166710A1 (es) Nuevos compuestos heterociclicos con actividad antiinflamatoria.
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων
DE602004018276D1 (de) Nitratester von phenylaminothiophen-essigsäurederivaten
CY1110467T1 (el) 2-(ετερο-)αρυλιο υποκατεστημενα παραγωγα τετραϋδροκινολινης

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee